Drug-induced immune thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 27, Issue 3, 2013, Pages 521-540

  Chong, Beng H ^a,b   Young Ill Choi, Philip ^b,c   Khachigian, Levon ^c   Perdomo, Jose ^b,c  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibodies; Drugs; Immune; Thrombocytopenia

Indexed keywords

ABCIXIMAB; AMRINONE; ANTIBODY; CEPHALOSPORIN; CORTICOSTEROID; EPTIFIBATIDE; HAPTEN; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; PENICILLAMINE; PENICILLIN DERIVATIVE; PHENYTOIN; QUININE; RANITIDINE; RIFAMPICIN; RITUXIMAB; SULFONAMIDE; TIROFIBAN; TRANEXAMIC ACID; VALPROIC ACID; VANCOMYCIN;

ANTIBODY DETECTION; ANTIGEN BINDING; APOPTOSIS; BLEEDING; CELL DAMAGE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DRUG BINDING; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED THROMBOCYTOPENIA; DRUG MEGADOSE; DRUG SENSITIZATION; EPITOPE MAPPING; FLOW CYTOMETRY; HEMOSTASIS; HERBAL MEDICINE; HISTORY OF MEDICINE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LABORATORY DIAGNOSIS; LABORATORY TEST; NONHUMAN; PANCYTOPENIA; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PURPURA; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HAPTENS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; PLATELET MEMBRANE GLYCOPROTEINS; QUININE; THROMBOCYTOPENIA;

EID: 84878260895     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.02.003     Document Type: Review

References (85)

1. Jones H., Tocantins L. The history of purpura haemorrhagica. Ann Med Hist 1933, 5:349-359.
2. Vipan W.H. Quinine as a cause of purpura. Lancet 1865, 2:37.
3. Aster R.H., Bougie D.W. Drug-induced immune thrombocytopenia. N Engl J Med 2007, 357:580-587.
4. Aster R.H., Curtis B.R., McFarland J.G., et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009, 7:911-918.
5. Chong B.H. Drug-induced immune thrombocytopenia. Platelets 1991, 2:173-181.
6. Fireman Z., Yust I., Abramov A.L. Lethal occult pulmonary hemorrhage in drug-induced thrombocytopenia. Chest 1981, 79:358-359.
7. Freiman J.P. Fatal quinine-induced thrombocytopenia. Ann Intern Med 1990, 112:308-309.
8. George J.N., Chong B.H., Li X. Drug-induced thrombocytopenia. Hemostasis and thrombosis: basic principles and clinical practice 2006, 1095-1102. Lippincott Williams & Wilkins, Philadelphia. 5th edition. R.W. Colman, V.J. Marder, A.W. Clowes (Eds.).
9. Chong B.H., Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 2009, 101:279-283.
10. Bottiger L.E., Bottiger B. Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia. Acta Med Scand 1981, 210:475-479.
11. Bottiger L.E., Westerholm B. Thrombocytopenia. II. Drug-induced thrombocytopenia. Acta Med Scand 1972, 191:541-548.
12. Danielson D.A., Douglas S.W., Herzog P., et al. Drug-induced blood disorders. JAMA 1984, 252:3257-3260.
13. Kaufman D.W., Kelly J.P., Johannes C.B., et al. Acute thrombocytopenic purpura in relation to the use of drugs. Blood 1993, 82:2714-2718.
14. Pedersen-Bjergaard U., Andersen M., Hansen P.B. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996, 239:509-515.
15. Pedersen-Bjergaard U., Andersen M., Hansen P.B. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol 1997, 52:183-189.
16. Pedersen-Bjergaard U., Andersen M., Hansen P.B. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol 1998, 54:701-706.
17. Perdomo J., Yan F., Ahmadi Z., et al. Quinine-induced thrombocytopenia: drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011, 117:5975-5986.
18. Ackroyd J.F. Allergic purpura, including purpura due to foods, drugs and infections. Am J Med 1953, 14:605-632.
19. Shulman N.R. Immunoreactions involving platelets. A steric and kinetic model for formation of a complex from a human antibody, quinidine as a haptene, and platelets; and for fixation of complement by the complex. J Exp Med 1958, 107:665-690.
20. Shulman N.R. A mechanism of cell destruction in individuals sensitized to foreign antigens and its implications in auto-immunity. Ann Intern Med 1964, 60:506-521.
21. Garratty G. Immune cytopenia associated with antibiotics. Transfus Med Rev 1993, 7:255-267.
22. Murphy M.F., Riordan T., Minchinton R.M., et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. Br J Haematol 1983, 55:155-160.
23. Shantsila E., Lip G.Y., Chong B.H. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009, 135:1651-1664.
24. Chong B.H., Berndt M.C., Koutts J., et al. Quinidine-induced thrombocytopenia and leukopenia: demonstration and characterization of distinct antiplatelet and antileukocyte antibodies. Blood 1983, 62:1218-1223.
25. Asvadi P., Ahmadi Z., Chong B.H. Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003, 102:1670-1677.
26. Burgess J.K., Lopez J.A., Berndt M.C., et al. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: characterization of the epitopes. Blood 1998, 92:2366-2373.
27. Chong B.H., Du X.P., Berndt M.C., et al. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991, 77:2190-2199.
28. Christie D.J., Mullen P.C., Aster R.H. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest 1985, 75:310-314.
29. Smith M.E., Reid D.M., Jones C.E., et al. Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent. J Clin Invest 1987, 79:912-917.
30. Peterson J.A., Nelson T.N., Kanack A.J., et al. Fine specificity of drug-dependent antibodies reactive with a restrictive domain of platelet GPIIIa. Blood 2008, 111:1234-1239.
31. Bougie D.W., Wilker P.R., Aster R.H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 2006, 108:922-927.
32. Burgess J.K., Lopez J.A., Gaudry L.E., et al. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX-specific quinine-dependent antibodies. Blood 2000, 95:1988-1992.
33. Gentilini G., Curtis B.R., Aster R.H. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998, 92:2359-2365.
34. Xiong J.P., Stehle T., Diefenbach B., et al. Crystal structure of the extracellular segment of integrin alphaV/beta3. Science 2001, 294:339-345.
35. Mo X., Nguyen N.X., McEwan P.A., et al. Binding of platelet glycoprotein Ibbeta through the convex surface of leucine-rich repeats domain of glycoprotein IX. J Thromb Haemost 2009, 7:1533-1540.
36. Jürgen K., Schwede T. The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res 2004, 32:D230-D234.
37. Kiefer F., Arnold K., Künzli M., et al. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 2009, 37:D387-D392.
38. Dill K.A. Denatured states of proteins. Annu Rev Biochem 1991, 60:795-825.
39. Li R. A hypothesis that explains the heterogeneity of drug-induced immune thrombocytopenia. Blood 2010, 115:914.
40. Topol E.J., Byzova T.V., Plow E.F. Platelet GPIIb-IIIa blockers. Lancet 1999, 353:227-231.
41. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997, 96:1445-1453.
42. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998, 339:436-443.
43. Coons J.C., Barcelona R.A., Freedy T., et al. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005, 39:368-372.
44. Patel S., Patel M., Din I., et al. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology 2005, 56:351-355.
45. Rezkalla S.H., Hayes J.J., Curtis B.R., et al. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 2003, 58:76-79.
46. Bougie D.W., Wilker P.R., Wuitschick E.D., et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002, 100:2071-2076.
47. Billheimer J.T., Dicker I.B., Wynn R., et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002, 99:3540-3546.
48. Artoni A., Li J., Mitchell B., et al. Integrin beta3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A 2004, 101:13114-13120.
49. Du X., Gu M., Weisel J.W., et al. Long range propagation of conformational changes in integrin alpha IIb beta 3. J Biol Chem 1993, 268:23087-23092.
50. Frelinger A.L., Du X.P., Plow E.F., et al. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991, 266:17106-17111.
51. Honda S., Tomiyama Y., Pelletier A.J., et al. Topography of ligand-induced binding sites, including a novel cation-sensitive epitope (AP5) at the amino terminus, of the human integrin beta 3 subunit. J Biol Chem 1995, 270:11947-11954.
52. Jennings L.K., Haga J.H., Slack S.M. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 2000, 84:1095-1102.
53. Kouns W.C., Newman P.J., Puckett K.J., et al. Further characterization of the loop structure of platelet glycoprotein IIIa: partial mapping of functionally significant glycoprotein IIIa epitopes. Blood 1991, 78:3215-3223.
54. Kouns W.C., Wall C.D., White M.M., et al. A conformation-dependent epitope of human platelet glycoprotein IIIa. J Biol Chem 1990, 265:20594-20601.
55. Loftus J.C., Plow E.F., Frelinger A.L., et al. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A 1987, 84:7114-7118.
56. Bougie D.W., Rasmussen M., Zhu J., et al. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of alphaIIb/beta3 integrin. Blood 2012, 119:6317-6325.
57. Chong B.H. Drug-induced thrombocytopenia: MIBS trumps LIBS. Blood 2012, 119:6177-6178.
58. Jubelirer S.J., Koenig B.A., Bates M.C. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999, 61:205-208.
59. Dery J.P., Braden G.A., Lincoff A.M., et al. Final results of the ReoPro readministration registry. Am J Cardiol 2004, 93:979-984.
60. Curtis B.R., Divgi A., Garritty M., et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004, 2:985-992.
61. Curtis B.R., Swyers J., Divgi A., et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002, 99:2054-2059.
62. Mascelli M.A., Lance E.T., Damaraju L., et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998, 97:1680-1688.
63. Newland A.C., Macey M.G. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994, 69:61-67.
64. Bougie D.W., Nayak D., Boylan B., et al. Drug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopenia. Blood 2010, 116:3033-3038.
65. Liang S.X., Pinkevych M., Khachigian L.M., et al. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood 2010, 116:1958-1960.
66. Li Z., Nardi M.A., Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 2005, 106:572-576.
67. Nardi M., Feinmark S.J., Hu L., et al. Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway. J Clin Invest 2004, 113:973-980.
68. Nardi M., Tomlinson S., Greco M.A., et al. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001, 106:551-561.
69. Olsson B., Andersson P.O., Jernås M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
70. McMillan R., Luiken G.A., Levy R. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978, 239:2460-2462.
71. Hoffman R., Zaknoen S., Yang H.H. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985, 312:1170-1174.
72. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
73. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
74. Greinacher A., Fuerll B., Zinke H., et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009, 114:1250-1253.
75. Perdomo J., Yan F., Chong B.H. A megakaryocyte with no platelets: anti-platelet antibodies, apoptosis, and platelet production. Platelets 2013, 24(2):98-106.
76. Piguet P.F., Vesin C. Modulation of platelet caspases and life-span by anti-platelet antibodies in mice. Eur J Haematol 2002, 68:253-261.
77. Li J., Kuter D.J. The end is just the beginning: megakaryocyte apoptosis and platelet release. Int J Hematol 2001, 74:365-374.
78. Poujol C., Ware J., Nieswandt B., et al. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol 2002, 30:352-360.
79. Takahashi R., Sekine N., Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999, 93:1951-1958.
80. Arnold J., Ouwehand W.H., Smith G.A., et al. A young woman with petechiae. Lancet 1998, 352:618.
81. George J.N., Raskob G.E., Shah S.R., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998, 129:886-890.
82. Chong B.H. Diagnosis of drug-induced thrombocytopenia. Int J Lab Hematol 2008, 30:10-11.
83. Chong B.H., Keng T.B. Advances in the diagnosis of idiopathic thrombocytopenic purpura. Semin Hematol 2000, 37:249-260.
84. Cimo P.L., Pisciotta A.V., Desai R.G., et al. Detection of drug-dependent antibodies by the 51Cr platelet lysis test: documentation of immune thrombocytopenia induced by diphenylhydantoin, diazepam, and sulfisoxazole. Am J Hematol 1977, 2:65-72.
85. Karpatkin M., Siskind G.W., Karpatkin S. The platelet factor 3 immunoinjury technique re-evaluated. Development of a rapid test for antiplatelet antibody. Detection in various clinical disorders, including immunologic drug-induced and neonatal thrombocytopenias. J Lab Clin Med 1977, 89:400-408.